

Dedicated to you

Financial Statements

Ceylon Hospitals PLC

For the 2nd Quarter ended 30th September 2022

Consolidated Statement of Profit or Loss and Other Comprehensive Income Accumulated Period of 6 Months								hs
	Gre	Group Company				Group		
	03 Months	03 Months	03 Months	03 Months	6 Months	6 Months	6 Months	6 Months
	Ended	Ended	Ended	Ended	Ended	Ended	Ended	Ended
	30/09/2022	30/09/2021	30/09/2022	30/09/2021	30/09/2022	30/09/2021	30/09/2022	30/09/2021
	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000
Revenue	1,935,334	2,100,407	1,090,224	1,430,105	3,579,817	3,980,538	1,996,441	2,689,770
Cost of Sales	(785,656)	(743,319)	(480,497)	(554,387)	(1,406,332)	(1,477,865)	(823,087)	
Gross Profit	1,149,678	1,357,088	609,727	875,718	2,173,485	2,502,673	1,173,354	1,618,690
Gross Front	1,142,070	1,337,000	000,121	075,710	2,173,403	2,302,073	1,175,554	1,010,070
Other Operating Income	48,833	15,866	15,183	11,617	35,665	24,481	23,989	16,309
Administrative Expenses	(666,812)	(810,571)	(425,869)	(602,898)	(1,288,240)	(1,510,204)	(823,762)	(1,104,374)
Other Operating Expenses	(203,973)	(172,074)	(91,400)	(116,087)	(400,623)	(334,394)	(211,896)	(226,031)
Results from Operating Activities	327,726	390,309	107,641	168,351	520,287	682,556	161,685	304,594
Finance Cost	(14,743)	(16,596)	(11,876)	(16,480)	(30,326)	(40,468)	(24,554)	(39,247)
Finance Income	65,125	15,344	28,270	94,187	130,465	34,986	241,425	246,694
Gain on Bargain Purchase	03,123	13,344	20,270) -1 ,107	150,405	12,002	241,425	240,024
Share of Profit of an Equity Accounted Investee	_	_	_	_	_	13,263	_	_
Profit before Taxation	378,108	389,056	124,035	246,058	620,426	702,338	378,556	512,041
Tront before Tuation	370,100	307,030	124,033	240,030	020,420	702,330	570,550	-
Taxation	(88,329)	(95,014)	(11,731)	(46,889)	(123,643)	(178,556)	(26,876)	(88,655)
Net Profit after Taxation	289,779	294,042	112,304	199,169	496,783	523,782	351,680	423,386
Other Comprehensive Income								
Items will not be reclassified to profit or loss Net Change in Fair Value on Equity Investments at								
FVOCI	3,922	8	(1,632)	8	2,042	64	28	64
Other Comprehensive Income for the Year	3,922	8	(1,632)	8	2,042	64	28	64
Total Comprehensive Income for the Year	293,701	294,050	110,672	199,177	498,825	523,846	351,708	423,450
10 1 00 10 2		274,030	110,072	177,177	470,023	323,040	331,700	723,730
Profit Attributable to:								
Equity Holders of the Parent	251,147	244,288	112,304	199,169	435,446	437,979	351,680	423,386
Non-Controlling Interest	38,632	49,755	-	-	61,337	85,803	-	-
	289,779	294,042	112,304	199,169	496,783	523,782	351,680	423,386
Total Comprehensive Income Attributelle to								
Total Comprehensive Income Attributable to: Equity Holders of the Parent	254,023	244.206	110 472	100 177	437,109	438,043	251 700	122 150
± •	,	244,296	110,672	199,177	,	*	351,708	423,450
Non-Controlling Interest	39,678 293,701	49,755 294,050	110,672	199,177	61,716 498,825	85,803 523,846	351,708	423,450
	293,701	474,030	110,072	177,1//	470,025	323,040	331,700	423,430
Earnings per Share - Basic	7.41	7.21	3.32	5.88	12.86	12.93	10.38	12.50
= = =					•			

The above figures are provisional and subject to audit.

Consolidated Statement of Financial Position

GROUP	COMPANY		GRO	OUP	COMP	ANY
Audited	Audited		Unaudited	Unaudited	Unaudited	Unaudited
As at	As at		As at	As at	As at	As at
31/03/2022	31/03/2022		30/09/2022	30/09/2021	30/09/2022	30/09/2021
Rs. '000	Rs. '000		Rs. '000	Rs. '000	Rs. '000	Rs. '000
		ASSETS				
		Non-Current Assets				
8,481,203	5,592,128	Property, Plant and Equipment	9,186,655	7,941,871	6,169,527	5,287,830
288,954	288,954	Right of Use Assets	286,690	204,321	284,060	204,321
-	1,457,821	Investments in Subsidiary	-	-	1,457,821	1,457,821
272,923	71,416	Other Financial Assets	298,841	332,728	74,114	67,532
890	=	Prepaid Rent		716	-	
9,043,970	7,410,319	_	9,772,186	8,479,636	7,985,522	7,017,504
		_				
925 140	(02 571	Current Assets	051 700	502.760	750 537	502.029
835,149	,	Inventories Trade and Other Receivables	951,788	593,760	750,526	503,038
306,454		Trade and Other Receivables	335,117	429,157	201,081	243,957
252,441		Prepayments	671,170	203,421	459,130	153,405
1,934		Amount Due from Related Parties	4,765	1,942	70,922	79,682
1,451,388	,	Other Financial Assets	1,018,082	939,384	397,222	131,638
13,278		Tax Refund Due	13,259	-	13,259	124 122
898,189		_Cash and Cash Equivalents	501,920	693,099 2,860,763	195,754	124,132
3,758,833 12,802,803	1,981,341	Total Assets	3,496,101 13,268,287	11,340,399	2,087,894 10,073,416	1,235,852 8,253,356
12,802,803	9,391,000	= 10tal Assets	13,200,207	11,340,333	10,073,410	6,233,330
		EQUITY AND LIABILITIES				
		Equity Attributable to Equity holders of the parent				
916,366	916.366	Stated Capital	916,366	916,366	916,366	916,366
2,691,662		Revaluation Reserve	2,691,662	2,691,662	2,134,544	2,134,544
65,868	, ,	Fair Value Reserve	67,531	68,500	628	192
3,873,950		Revenue Reserves	4,140,032	3,281,025	2,877,751	2,301,393
7,547,846	5,746,946		7,815,591	6,957,553	5,929,289	5,352,495
734,254	-	Non-Controlling Interests	759,599	691,378	, , , <u>-</u>	-
8,282,100	5,746,946		8,575,190	7,648,931	5,929,289	5,352,495
		- 1				
		Non-Current Liabilities				
1,701,501		Interest Bearing Loans and Borrowings	1,882,377	881,800	1,808,464	831,341
-		Deferred Revenue	-	-	28,785	32,589
177,998		Retirement Benefit Obligations	182,741	247,654	159,371	221,519
707,793		_Deferred Tax Liabilities	717,402	649,962	452,599	440,809
2,587,292	2,247,106		2,782,520	1,779,416	2,449,219	1,526,258
24455	0.4.505	Current Liabilities	400 #44	222.250	454044	10 - 10 -
246,765		Bank Overdraft	188,526	233,260	154,964	126,197
306,060		Interest Bearing Loans and Borrowings	316,774	368,070	268,043	328,959
1,247,893		Trade and Other Payables	1,296,202	1,190,551	770,656	806,833
127,894		Taxation Payable	87,723	118,397	13,121	54,393
4,799		Amount Due to Related Parties	21,352	1,774	488,124	58,221
1,933,411	1,397,608		1,910,577	1,912,052	1,694,908	1,374,603
12,802,803	9,391,660	_ Total Equity and Liabilities	13,268,287	11,340,399	10,073,416	8,253,356

The above figures are provisional and subject to audit.

Sgd

Thusitha Rubasinghe

Chief Financial Officer

The Board of Directors is responsible for the preparation and presentation of these Financial Statements. Signed for and on behalf of the Board by,

Sgd **A E Tudawe** Chairman Sgd U D Tudawe Director

10th November 2022

CEYLON HOSPITALS PLC STATEMENT OF CHANGES IN EQUITY

\sim			
(+	ro	ш	n

	Rs. '000	Reserve Rs. '000	Reserve Rs. '000	Reserves Rs. '000	Rs. '000	Interests Rs. '000	Rs. '000
Balance as at 31st March 2021	916,366	2,691,662	68,436	2,951,439	6,627,903	592,626	7,220,529
Net Profit for the Year	-	-	-	982,324	982,324	127,202	1,109,526
Other Comprehensive Income							
Actuarial Gain on Gratuity Valuation	-	-	-	55,965	55,965	300	56,265
Deferred Tax on Gratuity Valuation	-	-	-	(6,342)	(6,342)	332	(6,010)
Prior Year Adjustments - Inventory Written-off	-	-	-	(989)	(989)	(230)	(1,219)
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	(2,568)	-	(2,568)	217	(2,351)
Share Buyback	-	-	-	(54)	(54)	-	(54)
Total Comprehensive Income for the Year	-	-	(2,568)	1,030,904	1,028,335	127,822	1,156,158
Transactions with Owners in their capacity as Owners							
Non-Controlling Interest on Acquisition of Subsidiary	-	-	-	-	-	127,301	127,301
Dividend Paid - Ordinary Shares	-	-	-	(108,393)	(108,393)	(113,495)	(221,888)
	-	-	-	(108,393)	(108,393)	13,806	(94,587)
Balance as at 31st March 2022	916,366	2,691,662	65,868	3,873,950	7,547,845	734,254	8,282,100
Net Profit for the Six months ended 30 September 2022	-	-	-	435,446	435,446	61,337	496,783
Other Comprehensive Income							
Net Profit on equity instruments designnated at fair-							
-Value through other comprehensive income	-	-	1,663	-	1,663	379	2,042
Total Comprehensive Income for the Six Months Ended 30 September 2022	-	-	1,663	435,446	437,109	61,716	498,825
Transactions with Owners in their capacity as Owners							
Shares issued at Rights Issue by subsidiary	-	-	-	-	-	5,860	5,860
Dividend Paid - Ordinary Shares	-	-	-	(169,364)	(169,364)	(42,231)	(211,595)
	-	-	-	(169,364)	(169,364)	(36,371)	(205,735)
Balance as at 30th September 2022	916,366	2,691,662	67,531	4,140,032	7,815,590	759,599	8,575,190

Company

	Stated Capital Rs. '000	Revaluation Reserve Rs. '000	Fair Value Reserve Rs. '000	Revenue Reserves Rs. '000	Total Rs. '000
Balance as at 31st March 2021	916,366	2,134,544	128	1,986,400	5,037,438
Net Profit for the Year	-	-	-	770,550	770,550
Other Comprehensive Income					
Deferred Tax Effect on Revaluation Gain	-	-	-	-	-
Actuarial Gain on Gratuity Valuation	-	-	-	54,510	54,510
Deferred Tax Effect on Gratuity Valuation	-	-	-	(7,631)	(7,631)
Net Change in Fair Value on Equity Investments at FVTOCI	_	-	472	-	472
Total Comprehensive Income for the Year	-	-	472	817,429	817,901
Transactions with Owners in their capacity as Owners					
Dividend Paid - Ordinary Shares	-	-	-	(108,393)	(108,393)
	-	-	-	(108,393)	(108,393)
Balance as at 31st March 2022	916,366	2,134,544	600	2,695,436	5,746,946
Net Profit for the Six months ended 30 September 2022	-	-	-	351,680	351,680
Other Comprehensive Income					
Net Profit on equity instruments designnated at fair-					-
-Value through other comprehensive income	-	-	28	-	28
Total Comprehensive Income for the Six Months ended 30 September 2022	-	-	28	351,680	351,708
Transactions with Owners in their capacity as Owners					
Dividend Paid - Ordinary Shares	-	-	-	(169,364)	(169,364)
•	-	-	-	(169,364)	(169,364)
Balance as at 30th September 2022	916,366	2,134,544	628	2,877,751	5,929,289

Consolidated Statement of Changes in Equity For the period ended 30th September 2021

Groui	1

Group							
	Stated Capital	Revaluation Reserve	Fair Value Reserve	Revenue Reserves	Total	Non Controlling Interests	Total
	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000
Balance as at 31st March 2020	916,366	2,483,785	65,922	2,439,753	5,905,826	587,760	6,493,586
Net Profit for the Year	-	-	-	560,349	560,349	39,910	600,259
Other Comprehensive Income							
Deferred Tax Effect on Revaluation Gain	-	207,877	-	-	207,877	752	208,629
Actuarial Gain on Gratuity valuation	-	-	-	32,865	32,865	370	33,235
Deferred Tax Effect on Gratuity valuation	-	-	-	(7,007)	(7,007)	(610)	(7,617)
Net Change in Fair Value on Equity Investments at FVTOCI	_	-	2,514	-	2,514	554	3,068
Total Comprehensive Income for the Year	-	207,877	2,514	586,206	796,597	40,975	837,572
Transactions with Owners in their capacity as Owners							
Share of additional capital attributable to NCI	-	-	-	-	-	1,750	1,750
Dividend Paid - Ordinary Shares		-	-	(74,520)	(74,520)	(37,859)	(112,379)
		-	-	(74,520)	(74,520)	(36,109)	(110,629)
Balance as at 31st March 2021	916,366	2,691,662	68,436	2,951,439	6,627,903	592,626	7,220,530
Net Profit for the six months ended 30 September 2021	-	-	-	437,979	437,979	85,803	523,782
Other Comprehensive Income							
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	64	-	64	-	64
Total Comprehensive Income for the Six months ended 30 September 2021	-	-	64	437,979	438,043	85,803	523,846
Transactions with Owners in their capacity as Owners							
Non-Controlling Interest on Acquisition of Subsidiay	-	-	-	-	-	126,444	126,444
Dividend Paid - Ordinary Shares	-	-	-	(108,393)	(108,393)	(113,496)	(221,889)
		•	-	(108,393)	(108,393)	12,948	(95,444)
Balance as at 30th September 2021	916,366	2,691,662	68,500	3,281,025	6,957,553	691,378	7,648,931

Company

	Stated Capital	Revaluation Reserve	Fair Value Reserve	Revenue Reserves	Total
	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000
Balance as at 31st March 2020	916,366	1,931,063	-	1,588,064	4,435,493
Net Profit for the Year	-	-	-	446,118	446,118
Other Comprehensive Income					
Deferred Tax Effect on Revaluation Gain	-	203,481	-	-	203,481
Actuarial Gain on Gratuity valuation	-	-	-	31,090	31,090
Deferred Tax Effect on Gratuity valuation	-	-	-	(4,353)	(4,353)
Net Change in Fair Value on Equity Investments at FVTOCI		-	128	-	128
Total Comprehensive Income for the Year	-	203,481	128	472,855	676,464
Transactions with Owners in their capacity as Owners					
Dividend Paid - Ordinary Shares		-	-	(74,520)	(74,520)
	-	-	-	(74,520)	(74,520)
Balance as at 31st March 2021	916,366	2,134,544	128	1,986,400	5,037,438
Net Profit for the six months ended 30 September 2021	-	-	-	423,386	423,386
Other Comprehensive Income					
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	64	-	64
Total Comprehensive Income for the Six months ended 30 September 2021	-	-	64	423,386	423,450
Transactions with Owners in their capacity as Owners					
Dividend Paid - Ordinary Shares	-	-	-	(108,393)	(108,393)
·	-	-	-	(108,393)	(108,393)
Balance as at 30th September 2021	916,366	2,134,544	192	2,301,393	5,352,495

Statement of Cash Flows

Group	Company		Gro	up	Comp	anv
Audited	Audited		Unaudited	Unaudited	Unaudited	Unaudited
12 Months	12 Months		6 Months	6 Months	6 Months	6 Months
Ended	Ended		Ended	Ended	Ended	Ended
31/03/2022	31/03/2022		30/09/2022	30/09/2021	30/09/2022	30/09/2021
Rs '000	Rs '000		Rs '000	Rs '000	Rs '000	Rs '000
		Cash Flows from/ (Used in) Operating Activities				
1,388,911	902,276	Net Profit Before Income Tax Expenses	620,426	702,338	378,556	512,041
		Adjustments for:				
25,388		Inventory Write-off/(Write in)	(6,856)	18,986	(470)	16,408
19,490		Bad Debts Write-off	495	798	494	797
339,848		Depreciation Charge for the Year	181,499	163,506	100,420	89,255
108,031		Amortisation of Right to use assets	56,759	52,037	56,759	52,037
(81,822)		Finance Income	(130,465)	(34,986)	(241,425)	(246,694)
80,567		Finance Cost	30,326	40,468	24,554	39,247
100		Amortisation of Deferred Rent Expenses/(Income)	(1,740)	274	(2,685)	(671)
(5,202)		(Profit)/ Loss on Disposal of Property, Plant and Equipmen	2.504	-	(2.500)	-
(32,917)		Fair value(Gain)/Loss on Financial Instruments	2,506	610	(2,590)	64
-	-	Foreign Exchange (Gain)/Loss	(18,326)	-	(10,441)	-
(11.704)	-	Reversal of provisions	(59,000)	- (12.262)	(59,000)	-
(11,724)	25.090	Share of Profit of an Equity Accounted Investee	10.500	(13,263)	16 200	16 200
28,948 1,859,618		Provision for Defined Benefit Plans Operating Profit before Working Capital Changes	19,500 695,124	19,460 950,227	16,200 260,372	16,200 478,683
1,039,010	1,003,270	Operating Front before working Capital Changes	093,124	930,227	200,372	470,003
(324,660)	(264.887)	(Increase)/Decrease in Inventories	(109,782)	(76,869)	(56,485)	(68,971)
(184,978)		(Increase)/Decrease in Trade and Other Receivables	(429,561)	(239,969)	(240,256)	(119,755)
576,763		Increase/(Decrease) in Trade and Other Payables	107,309	519,421	(32,794)	422,117
(171,712)		(Increase)/Decrease Related Party Dues	13,722	(174,744)	374,602	(115,419)
1,755,031		Cash Generated from Operations	276,812	978,065	305,439	596,655
-,,,,	-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		,	.,.,	2 2 2 4 2 2 2	,
(51,361)	(41,581)	Finance Cost Paid	(30,326)	(33,376)	(24,554)	(32,155)
(37,567)	(30,868)	Defined Benefit Plan Costs Paid	(14,757)	(14,688)	(13,618)	(11,759)
(160,869)	(109,439)	Income Tax Paid	(154,188)	(108,082)	(87,037)	(76,156)
1,505,234	901,262	Net Cash from Operating Activities	77,541	821,920	180,230	476,585
		Cash Flows from/ (used in) Investing Activities				
(1,109,961)	(697,335)	Acquisition of Property, Plant and Equipment	(886,950)	(392,779)	(677,819)	(295,468)
-	-	Acquisition of Right to use assets	-	(1,843)	-	(1,843)
8,750		Proceeds from Sale of Property, Plant and Equipment	-	2,040	-	1,750
(422,851)		(Acquisition)/ Disposal of other Investments	407,513	122,093	261,546	(9,084)
81,822	, -	Income from Investments	130,465	34,986	241,425	246,694
(1,442,240)	(975,988)	Net Cash Flows from/ (used in) Investing Activities	(348,972)	(235,502)	(174,848)	(57,950)
		Cash Flows from/ (used in) Financing Activities				
1,019,153	900 900	Cash Flows from/ (used in) Financing Activities Receipts from Interest Bearing Loans and Borrowings	300,000	170,310	300,000	137,319
(740,022)		Re-payments to Interest Bearing Loans and Borrowing	(105,637)	(557,318)	(74,770)	(539,438)
(135,537)		Lease Rent Payment	(55,226)	(62,506)	(55,226)	(62,506)
(54)	(133,337)	Share buy back	(33,220)	(02,300)	(33,220)	(02,300)
248,399	_	Non-Controlling Interest on Acquisition of Subsidiary	_	126,444	_	_
240,399		Proceeds on Shares issued at Rights Issue	5,860	120,444	-	-
(221,888)	(108 393)	Dividends Paid	(211,595)	(221,888)	(169,364)	(108,393)
170,051		Net Cash Flows from/ (used in) Financing Activities	(66,598)	(544,957)	640	(573,016)
170,031	(12,023)		-	(511,751)	-	(5,5,010)
233,044	(117,549)	Net Increase/ (Decrease) in Cash and Cash Equivalents	(338,029)	41,460	6,022	(154,381)
418,379	152,317		651,423	418,379	34,768	152,317
651,423		Cash and Cash Equivalents at the End of the Year	313,394	459,839	40,790	(2,064)
		Analysis of Cash and Cash Equivalents	-	•	-	
(246,766)	(94,527)	Bank Overdraft	(188,526)	(233,260)	(154,964)	(126,197)
898,189		Cash in Hand and at Bank	501,920	693,099	195,754	124,132
651,423	34,768	-	313,394	459,839	40,790	(2,064)
		= =	-		•	

Explanatory Notes

01. CORPORATE INFORMATION

Ceylon Hospitals PLC is a public limited company incorporated and domiciled in Sri Lanka and listed on the Colombo Stock Exchange. Ordinary shares of the company are listed on the Colombo Stock Exchange.

02. INTERIM CONDENSED FINANCIAL STATEMENTS

The financial statements for the six months ended 30 September 2022, includes "the Company" referring to Ceylon Hospitals PLC, as the holding company and "the Group" referring to the companies whose accounts have been consolidated therein.

03. APPROVAL OF FINANCIAL STATEMENTS

The interim condensed financial statements of the Group and the Company for the period ended 30 September 2022 were authorised for issue by the Board of Directors on 10th November 2022.

04. BASIS OF PREPARATION AND CHANGES TO ACCOUNTING POLICIES

4.1 Basis of preparation

The interim financial statements for the six months ended 30 September 2022 have been prepared in accordance with LKAS 34 Interim Financial Reporting.

The interim condensed financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements as at 31 March 2022.

4.2 Fair value measurement and related fair value disclosures

The fair values of all the financial assets and financial liabilities recognised during the quarter were not materially different from the transaction prices at the date of initial recognition. There were no transfers between Level 1 and Level 2 and no transfers into or out of Level 3 categories as per the fair value hierarchy, during the quarter. The fair value changes on financial instruments in Level 3 category was properly recorded in the statement of other comprehensive income and there were no purchases and/or disposals during the period.

Fair valuation was done as of 30 September 2022 for all unquoted equity shares classified as Level 3 within the fair value hierarchy according to fair valuation methodology. Fair value would not significantly vary if one or more of the inputs were changed.

05. There were no contingent liabilities as at the Balance Sheet date which would require adjustment or disclosure in the Financial Statements.

06. Events occuring after the Balance Sheet date

The Inland Revenue (Amendment) Bill published on 11th October 2022 that is currently subject to Parliament approval, stipulates that the standard corporate income tax be increased to 30%. As such, upon Parliamentary approval the Group companies will be liable to pay income tax at 30% except for Durdans Medical and Surgical Hospital (Pvt) Ltd that will continue at a tax rate of 15% being BOI approved entity.

- 07. Related party transactions for the quarter ended 30 September 2022 were reviewed by the Related Party Transactions Review Committee and it was decided there were no transactions requiring Board Approval, immediate CSE disclosure or Shareholder approval.
- 08. Amrak Institute of Medical Sciences (Pvt) Ltd which is a Sub-Subsidiary of Ceylon Hospital PLC issued 1,586,000 ordinary shares for Rs. 15,860,000/- at Rights Issue on 01 August 2022.

Related Party Transactions For the Six Months ended 30 September 2022 - In LKR '000s

Name of the Related Party	Relationship	Transactions	Nature	Aggregate Value of Related Party Transactions
Durdans Management Services Ltd	Ultimate Parent	Management fee Rendering of utilities and other cost Total	Recurrent Recurrent	22,117 1,017 23,134
Durdans Medical and Surgical Hospital (Pvt) Ltd	Subsidiary	Sales of Drugs and consumables Rendering of medical services Rendering of utilities and other cost Purchases of Drugs and consumables Receiving of medical services Receiving of utilities and other cost Total	Recurrent Recurrent Recurrent Recurrent Recurrent Recurrent	19,862 229,653 259,097 19,814 77,202 53,961 659,589
Durdans Heart Centre (Pvt) Ltd	Subsidiary	Sales of Drugs and consumables Rendering of medical services Rendering of utilities and other cost Purchases of Drugs and consumables Receiving of medical services Receiving of utilities and other cost Total	Recurrent Recurrent Recurrent Recurrent Recurrent Recurrent	2,211 48,667 51,783 5,443 22,130 169
Amrak Institute of Medical Sciences (Pvt) Ltd	Subsidiary	Rendering of utilities and other cost Total	Recurrent	1,767 1,767
Ceygen Biotech (Pvt) Ltd	Subsidiary	Sale of Drugs and consumables Receiving of utilities and other cost Total	Recurrent Recurrent	304 23 327
Commercial Marketing Distributors (Pvt) Ltd	Affiliate	Sale of Drugs and consumables Purchases of Drugs and consumables Total	Recurrent Recurrent	1,621 78,722 80,343
Tudawe Brothers (Pvt) Ltd	Affiliate	Rendering of medical services Total	Recurrent	111 111
Name of the Related Party	Relationship	Transactions	Nature	Aggregate Value of Related Party Transactions
Tudawe Brothers (Pvt) Ltd	Affiliate	Project 2022 Construction Cost Total	Non Recurrent	148,977 148,977

Share Information

Number of Shares Represented in Stated Capital

 Voting Shares
 25,527,272

 Non-Voting Shares
 8,345,454

 Total
 33,872,726

Public Shareholding as at 30th September 2022

1 done shareholding as at coth september 2022		
	Voting	Non-Voting
Number of shareholders	2,331	1,263
Number of shares	5,657,963	4,221,339
Holding Percentage	22.16%	50.58%
Float Adjusted Market Capitalisation (Rs Mn)	761	
Float Adjusted Market Capitalisation Option	Less than 5 Bn	(Option 3)

Director's and Chief Executive Officer's Shareholding as at 30th September 2022

	Number of Shares		
	Voting	Non-Voting	
Mr A E Tudawe	215,202	-	
Mr U D Tudawe	170,616	-	
Dr A D P A Wijegoonewardene	220,582	-	
Mr Y N R Piyasena	501,000	-	
Mr A S Abeyewardene	1,440	1,200	
Mr A D B Talwatte	1,000	-	
Mr. A.V.R. De Silva Jayatilleke	100	-	
Mr. A.S. Tudawe	48	1,000	

Market Prices recorded during the Quarter

and the second s	Highest		Lowest		Last	
	Traded Price 2022/23 2021/22		Traded Price 2022/23 2021/22		Traded Price 2022/23 2021/22	
	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.
Voting	170.00	130.00	106.75	100.00	134.50	122.00
	04/08/2022	13/09/2021	11/07/2022	01/09/2021	30/09/2022	30/09/2021
Non - Voting	127.50	118.50	85.50	86.10	111.00	103.50
	13/09/2022	13/09/2021	11/07/2022	26/07/2021	30/09/2022	30/09/2021

Per Share Ratios

	Group		Con	Company	
	As at 30/09/2022 Rs	As at 30/09/2021 Rs	As at 30/09/2022 Rs	As at 30/09/2021 Rs	
Earnings Per Share	12.86	12.93	10.38	12.50	
Net Asset Per Share	230.73	205.40	175.05	158.02	

Top 20 Shareholders Listed as at 30 September 2022

Voting Shareholders

Name of the Shareholder	Country of	Number of	Holding
	Residence	Shares	%
Durdans Management Services Ltd	Sri Lanka	17,471,382	68.44
Lawrance Tudawe Management Services (Pvt) Ltd	do	600,077	2.35
Mr Y N R Piyasena	do	501,000	1.96
Mr Deen Mohamed Fazal Aslam	do	472,549	1.85
Galle Face Capital Partners PLC	do	400,000	1.57
Mr. Merill J. Fernando	do	367,530	1.44
Cargo Boat Development Company PLC	do	305,485	1.20
MJF Holdings Ltd	do	270,981	1.06
Mr.D.G. Wijemanna	do	268,577	1.05
Mr.R.P. Weerasooriya	do	238,991	0.94
Mr. A. D. P. A. Wijegoonewardene	do	220,582	0.86
Mr. A. E. Tudawe	do	215,202	0.84
Mrs H. K. Weerasinghe	do	200,000	0.78
Mrs L. I. Weerasinghe	do	200,000	0.78
Mrs T. T. Weerasinghe	do	200,000	0.78
Mr. U. D. Tudawe	do	170,616	0.67
Mr. H. L. Tudawe	do	165,114	0.65
Mr. A. D. Tudawe	do	161,984	0.63
Mr. P.V. Tudawe	do	156,978	0.61
Mr.A.H.Munasinghe	do	86,326	0.34
	•	22,673,374	88.82

Non-Voting Shareholders

Name of the Shareholder	Country of Residence	Number of Shares	Holding %
Durdans Management Services Ltd	Sri Lanka	2,726,540	32.67
Employee Provident Fund	do	1,154,371	13.83
MJF Holdings Ltd	do	598,646	7.17
E W Balasuriya & Co. (Pvt) Ltd	do	330,619	3.96
Mr. D. Ratnayake	do	146,866	1.76
Mr. A. H. Munasinghe	do	138,614	1.66
Tudawe Engineering Services (Pvt) Ltd	do	91,986	1.10
Mr. D. A. Cabraal	do	82,500	0.99
Mr. S. S. Sithambaranathan	do	77,753	0.93
Mr. A. D. Tudawe	do	71,151	0.85
Mr. P. S. De Mel	do	70,822	0.85
Peoples Leasing & Finance PLC /Mr. P. A. I. S. Perera	do	70,100	0.84
Ms. T. T. Weerasinghe	do	68,485	0.82
Commercial Bank of Ceylon PLC A/C No. 04	do	61,100	0.73
Mr. D.P. L. De Mel	do	58,908	0.71
Saman Villas Limited	do	58,462	0.70
Mr. H A Cabraal	do	50,000	0.60
Mr. G. D. M. Ranasinghe	do	50,000	0.60
Mr. U. D. Wickremesooriya	do	50,000	0.60
Hallsville Trading Group INC	do	49,123	0.59
		6,006,046	71.97

CORPORATE INFORMATION

Name of Company

Ceylon Hospitals PLC

Brand Name

DURDANS

Legal Form

A quoted public company with limited liability incorporated in Sri Lanka under the Companies Ordinance No.51 of 1938 and registered under the Companies Act No.07 of 2007.

Company Registration Number

PQ 113

Stocks Exchange Listing

The Ordinary Shares of the Company are listed on the Colombo Stock Exchange of Sri Lanka.

Registered Office

No.03, Alfred Place, Colombo 03.

Bankers

Bank of Ceylon Commercial Bank of Ceylon PLC DFCC Bank PLC Hatton National Bank PLC National Development Bank PLC Nations Trust Bank PLC Sampath Bank PLC Seylan Bank PLC Union Bank PLC People's Bank

Auditors

Messers.B.R.De.Silva & Co. Chartered Accountants No.22/4,Vijaya Kumaratunga Mawatha Colombo 05.

Ceylon Hospitals PLC

Lawyers

Mr.D.F.R.Jayamaha Hector Jayamaha Law Office, No.228,Thimbirigasyaya Road, Colombo 05.

Secretaries

Nexia Corporate Consultants (Pvt) Ltd No 181, Nawala road, Narahenpita.

Registrars

S S P Corporate Services (Pvt) Ltd 546, Galle Road, Colombo 03.